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Abstract  
Recent studies suggest that the incidence and mortality of amyotrophic lateral sclerosis (ALS) are increasing. 
Changing environmental factors could influence disease risk differently throughout life span, and also between 
genders, birth cohorts and seasons of birth. We aimed at describing long term ALS mortality trends in Norway 
between 1951 and 2014 by using age-period-cohort analysis. The Norwegian Cause of Death Registry provided 
ALS mortality data that were age- and sex-adjusted through direct standardization. Poisson regression analyses 
were used for identification of mortality trends and potential month of birth effects. We identified 5345 ALS 
cases, of which 54.7 % were men. ALS mortality increased throughout the whole period (p<0.001), with a mean 
annual increase of 1.14%. The increase was confined to those older than 60 years, but rates consistently dropped 
amongst the absolute oldest. The increase was mainly driven by birth cohort effects that increased from 1860 
until 1934 (p<0.001). No month of birth effect or change in sex ratio were found. The continuous increase in 
ALS mortality since 1951 is best explained by long-term changes in exposure to risk factors or in case 
ascertainment, affecting men and women equally in the generations born since 1860 and at least into 1934.  
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Despite advances in the understanding of the genetics of amyotrophic lateral sclerosis (ALS), the etiology is still 
largely unknown [1]. Several environmental and life style risk factors such as smoking, physical trauma, 
athleticism and low intake of polyunsaturated fatty acids have been suggested [2]. The susceptibility periods for 
these are not known, and exposure is likely to vary across generations. As mortality rates for ALS closely 
reflects incidence [3],  better understanding of long term trends in age- and sex-specific mortality rates may 
provide clues to disease etiology. Where standardized rates have the advantage of simplicity, age-period-cohort 
analyses provides more details on time effects for vital rates [4]. This analytical tool aims at distinguishing 
between changes resulting from birth cohort effects, period effects and age effects. Cohort effects reflect 
variations in disease risk that applies to all individuals born in the same period, and are associated with long-term 
exposures affecting different generations being exposed to different risks. Period effects result from external 
factors that equally affect all age groups at a particular calendar time. The age effect provides information on the 
rates of the disease in terms of different age groups. Earlier age-period-cohort analyses of ALS are limited, but 
findings lean towards cohort effects best explaining increase in rates [5-7]. No age-period-cohort analyses have 
been conducted on ALS in Norway. 
For ALS and other complex diseases, studies have suggested an association between month of birth and risk for 
disease [8-12]. Such an effect could be of minor magnitude, but never the less of great interest from an 
epidemiological perspective.  
With a relatively stable population, each person given a unique personal identification number and equal access 
to well-developed public health services, Norway is ideal for register-based studies. The Norwegian Cause of 
Death Registry (NCoDR) provides digitalized data for all deaths in Norway since 1951. NCoDR is based on 
death certificates (DCs) that are examined and controlled to ensure the diagnoses are plausible given the person’s 
age and gender. Given the characteristics of ALS, mortality data has proven fairly reliable [3,13], and has 
previously shown an increasing trend from 1961 to 1994 in Norway [13]. 
The aim of this study was to describe the mortality trends from ALS in Norway during the period 1951-2014, 
including potential age, period, cohort and month of birth effects.   
 
Materials and methods 
Data collection 
NCoDR collects and processes all information from all DCs. The direct, contributing and underlying cause of 
death is coded using the international classification of diseases (ICD). The following ICD systems have been 
used: ICD 6: 1951-57, ICD 7: 1958-68, ICD 8: 1969-85, ICD 9: 1986-95 and ICD 10: 1996-onwards. We 
searched all DCs in Norway from 1951 to 2014 containing codes corresponding to ALS mentioned anywhere on 
the DC. We used following corresponding codes for ALS: ICD 6 and 7: 356.0, 356.1, ICD 8: 348.0, 348.1, 348.2, 
ICD 9: 335.2, ICD 10: G12.2. Variables obtained for each case were gender, age (5-year bins), year of death (5 
year bins), year of birth (1-year bins), county and month of birth. General population data for the same period 
were obtained from Statistics Norway. 
To validate the data from NCoDR,  we searched all electronically available hospital files at Akershus University 
Hospital (2004-2013) and Haukeland University Hospital (2001-2005), for patients diagnosed with ALS (ICD 10: 
G12.2), and examined whether those deceased within 2014 be were coded as G12.2  in their respective DCs. 
Together, these hospitals provide neurological services to 20% of the population in Norway 
Statistical analysis  
For the purpose of graphical presentation the mortality rates were age-sex standardized using the 2010-14 
population as reference. 
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Poisson regression modeling was used for inference of longitudinal age and gender-specific trends. The 
following model was specified:  
log⁡(𝜇𝑖𝑗𝑘) = log(𝑝𝑒𝑟𝑠𝑜𝑛𝑦𝑒𝑎𝑟𝑠𝑖𝑗𝑘) +⁡𝛽0 +⁡β1𝑔𝑒𝑛𝑑𝑒𝑟𝑖 +⁡𝛽2𝑦𝑒𝑎𝑟𝑗 + 𝛽3𝑎𝑔𝑒𝑘 + 𝛽4𝑎𝑔𝑒𝑘
2 + 𝛽5𝑎𝑔𝑒𝑘
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where 𝜇𝑖𝑗𝑘 ⁡is the expected number of ALS deaths for gender i (0 for female, 1 for male) in year j for persons of 
age k. In this model the 5 year periods were coded on a continuous scale so that the regression coefficient 𝛽2is 
interpreted as the annual change in mortality over the whole study period. The same was done for the variable 
age. The second and third degree terms for age are included to capture the non-linear age distribution of ALS. To 
test if there is a trend after the last reported observation (13), the model was also fitted using data from after 
1994 only.   
To test whether there were longitudinal changes in mortality rates for gender or age, the model was extended to 
include interaction between age and year, and gender and year (compared with the basic model using Likelihood 
Ratio test). 
Age-Period-Cohort analysis was performed for the whole study period only, and followed the methodology 
described in Carstensen [14]. The Epi R package was used for the analysis. For identification constraints we used 
1980 as reference period and 1920 as reference cohort, with period effects set to be 0 on average.  
Data for birth months were tabulated in 5-year periods from 1886 to 1960. To test the hypothesis of a month of 
birth effect the following Poisson regression model were specified: 
log⁡(𝜇𝑖𝑘) = log(𝑏𝑖𝑟𝑡ℎ𝑠𝑖𝑘) + ⁡𝛽0 +⁡β1𝑏𝑖𝑟𝑡ℎ𝑝𝑒𝑟𝑖𝑜𝑑𝑖 +⁡𝛽2𝑏𝑖𝑟𝑡ℎ𝑝𝑒𝑟𝑖𝑜𝑑𝑖
2 +⁡𝛽3𝑘𝑚𝑜𝑏𝑘 
where 𝜇𝑖𝑘 ⁡is the expected number of ALS deaths for persons born in period i and month k. The birth period 
variable is used as a continuous variable.  The second order term were included to capture longer non-linear 
trends observed in the data, assumed to be an effect of low mortality in the more recent birth cohorts. The month 
of birth is a categorical variable with 12 levels.  
   
Results 
A total of 5345 ALS cases were identified from 1951-2014, of whom 2922 (54.7%) were men and 2423 (45.3%) 
were women. Out of 182 ALS cases diagnosed at Akershus University Hospital (2004-2013) and Haukeland 
University Hospital (2001-2005), 174 (96%) were retrieved in the NCoDR.   
The overall standardized mortality rate per 100,000 person years is given in figure 1. The average rates, 
standardized for sex and age, were 1.3 in 1951-1954, 1.9 in 1970-1974, 2.4 in 1990-1994 and 2.8 in 2010-2014. 
Crude rates were 1.0, 1.7, 2.3 and 2.8 correspondingly. 
ALS-related mortality increased consistently and significantly during the whole period (p < 0.001). This trend 
was almost identical in the two counties with fully developed neurological departments throughout the study 
period (Oslo and Hordaland including Bergen), compared to the rest of Norway (supplementary figure 1). Mean 
annual increase was 1.14%. Also after 1994, the latest reported observation [13],  the increase was significant 
(p=0.016), with a mean annual increase of 0.88%. The standardized increase in ALS mortality over the whole 
period was 97% for men and 141% for women. Men had 46% greater mortality rate than women over the entire 
study period (p < 0.001), but the increasing trend over time was not significantly different between the genders 





Fig.1 Amyotropchic lateral sclerosis mortality rate in Norway, 1951-2014. The rates are directly age -and sex 
standardized, using the Norwegian 2010-2014 population as reference 
 
As shown in figure 2 A, ALS-related mortality was greater amongst men in all age groups, it peaked at 75-79 
years for both genders, and declined markedly thereafter. The rise in period-specific rates was restricted to age-
groups older than 60 years, and after 1969 to age-groups older than 70 years (fig 2 B). Hence, mean age at death 
of ALS increased from about 62 years in 1951-54 to about 71 years in 2010-2014. Meanwhile, mean general life 
expectancy in Norway increased from 71 to 82 years.  
 
 
Fig.2 Amyotrophic lateral sclerosis mortality rates in Norway, 1951-2014, connected within genders in panel A, 




Figure 3 displays age-dependent rates by birth cohort and by period of death. In older cohorts, mortality rates 
increased more with successive birth years than in recent cohorts (3 A). During the study period, the mortality 
rates remained more or less unchanged for those aged less than 65 years, indicated by horizontal lines (panel 3 
B). For age-groups older than 65, and particularly for those older than 75 years, the rates increased steadily (3 B). 
Taken together, this indicates disproportional changes in mortality rates, depending on both year of birth and 
period of death. 
Table 1 shows the results from the fit of the age-period-cohort model for mortality rate. For our data, the full age 
period cohort model provided the best fit, with the cohort factor having greater impact than the period factor.  
Results of the full age-period-cohort model are shown in Figure 4. The cohort effect estimated from the full 
model showed that the relative risk of dying from ALS increased markedly up until birth year 1934, when it 
again decreased (4 A). The model estimates a 76% bigger risk of dying from ALS if born in 1930 compared to 
1880, regardless of age at death (4 A). Between 1934 and 1960 the cohort effect seems to decline, but 
estimations become more uncertain as few have yet reached the ALS susceptibility age.   
The period effect displays a U-formed curve with the chosen reference period (1980) at the bottom (Figure 4 B). 
There were no changes in the effect of period between early 1970ies and late 1990ies, whereas before and after 
that, period effects were relatively greater.  
Stratifying the data by age (older and younger than 70 years), the full age-period-cohort model provided the best 
fit for those younger than 70, whilst the age-cohort model fitted data best for those older than 70. The results 
were unchanged when the data was stratified by gender. Finally, shifting the constraints over to the cohort effect 
also provided the same qualitative interpretation (data not shown). 
 
 
Fig.3 Age-dependent mortality rates from amyotrophic lateral sclerosis in Norway 1951-2014, by birth cohort 





Fig.4 Age-period-cohort model of amyotrophic lateral sclerosis mortality in Norway, 1951-2014. Average period 
effect is constrained to be 0. The tilt of the curve is dependent on the constraints, but the curvature is not. Panel 
A displays estimated cohort effects relative to 1920. Panel B displays estimated period effects relative to 1980. 












Age                241 677.56    
Age-drift          240 482.17  1  195.38 < 0.001 
Age-Cohort         236 314.64  4  167.54 < 0.001 
Age-Period-
Cohort  
232 289.41  4   25.23 < 0.001 
Age-Period         236 472.93 -4 -183.52 < 0.001 
Age-drift          240  482.17 -4   -9.25   0.055 
 
Table 1 Results and comparison of age-period-cohort models of amyotrophic lateral sclerosis mortality in 
Norway, 1951-2014. The χ² model comparison test is performed sequentially from top to bottom. Decreasing 
residual deviance indicates a better fit. 
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Month of birth 
Out of our total 5345 ALS cases, 5129 were born between 1886 and 1960. In the same period 4415823 births 
were registered. A likelihood-ratio test for the effect of months on the number of ALS deaths was not significant 
(p=0.472). Supplementary table 1 displays the effect of being born in different months. Being born in May and 
October seemingly increases risk for ALS with a little less than 8 percent, however not to any statistically 
significant extent.  
 
Discussion 
We find continuously increasing ALS mortality in Norway from 1951 to the end of 2014, but stable sex ratio and 
no month of birth effect. The increase in mortality is restricted to those above 60 years of age, with a persistent 
drop amongst the absolutely oldest. Although there is evidence of period effects on ALS mortality particularly 
before 1970 and after 1990, cohort effects operating at least in generations born before 1934 seem to have the 
strongest overall impact on the increasing ALS mortality.   
Our study extends an earlier study carried out in Norway from 1961-1994 [13], showing that annual mortality 
rates from ALS increased from 1.52 in 1961 to 2.54 in 1994. An observed levelling off towards 1994 was only 
temporary; the increasing trend continued into 2014. Increasing mortality rates restricted to older age groups 
mirror findings in other countries [15,5,6,16-20]. The consistent decrease in period specific rates among the 
oldest age-groups (>80 years) supports the theory of ALS being an age-dependent disease, more than aging-
dependent [21]. Notably, age in this context most likely represents biological age more than chronological age, 
as mean age at onset of ALS is proportional to life expectancy with a constant factor between different 
populations [22]. Our finding of a similar increase in mean age of death from ALS and life expectancy in the 
general population in Norway concur with this notion. This constant relationship may suggest that factors 
influencing life expectancy also influence ALS onset. For the earliest (1951-54) and latest (2010-2014) 
observation periods in the current study, mean age at death of ALS relate to mean life expectancy with the 
following constant proportion: 62/73 ≈ 71/82 ≈ 0.85. It can be argued that it exists a subpopulation susceptible to 
ALS, and when life expectancy increases with time, more susceptible people will reach ages where ALS is 
expressed [23,24]. This theory is, however, not in conflict with environmental factors potentially influencing 
both ALS susceptibility and timing of death. It is possible that genetic factors play a relatively great etiological 
role in people with early debut of ALS, and that these are not affected by environmental factors to the same 
extent as those with later debut. If so, environmental changes could contribute to the increasing mortality trend 
restricted to older persons.  
Differences in sex-specific mortality rates also reflect  findings from other countries [25]. Some studies do 
however report narrowing of the gap between male to female mortality [26,5,6], and this was also suggested in 
Norway from 1961 to 1994 (13). Suggested explanations have been that men and women increasingly are being 
exposed to more similar arrays of environmental factors, alternatively a relative under-ascertainment of female 
cases in earlier periods. Converging sex-specific rates were not apparent in our study, although there was some 
fluctuation in the male: female ratio, from 1,12 at the lowest in 1991-1994 to 1,60 at the highest in 1951-1954. 
Such fluctuations are most likely random, and underscore the need of large data sets and long follow up.    
Birth cohort effects affect all individuals in a generation, irrespective of their age of death. Changing 
environmental exposures could explain such effects. ALS has been modelled as a disease where genes, 
environment and time work as different burdens up until a threshold for disease [1]. It is possible that 
environmental risk factors operate at young ages, and that different birth cohorts are unequally affected by such 
factors in regards to both frequency and intensity. We find increasing cohort effects between 1880 and 1934, 
indicating a higher risk for developing ALS at any age for those born 1934, compared to those born 1880. Our 
findings suggest that exposure to environmental factors linked to ALS etiology in both men and women have 
increased for those being young in the first half of the past century, but thereafter possibly levelled off or even 
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decreased. ALS mortality data from both France and Denmark [5,6] showed similar results; increasing ALS 
mortality rates in succeeding birth cohorts from 1880 to 1920. 
In our study, period of death also influenced the observed changes in ALS mortality. In contrast to cohort effects, 
period effects influence people across all ages, irrespective of their birth year. Decreasing period effects before 
1970 and an increasing trend after 1995 diverge from period effects found in Denmark [5], but resembles 
possible period effects found in Switzerland when applying the full age-period-cohort model [7]. It should be 
noted that the Danish study used both different selection of ICD systems (ICD 9 not included) and ICD codes 
(only 348.0 within ICD 8), possibly contributing to conflicting results. The factors underlying the observed 
period effects in the current study is unclear. The introduction of the disease modifying agent Riluzole in 1996, 
together with establishments of ALS-teams in the same period, may have given neurologists greater motivation 
for diagnosing ALS. Additionally, emerging possibilities for genetic testing may have improved case 
ascertainment, although probably not to any extent that influences mortality rates yet. Changes in different ICD 
versions and revisions of diagnostic criteria also have to be considered. Over the course of our study period, four 
different ICD versions were used. A more liberal inclusion of motor neuron disease sub-diagnoses within earlier 
versions (348.9 in ICD 8, 335.0, 335.1 and 335.9 in ICD 9) would have provided 165 additional cases (data not 
shown). The exclusion of these cases could have contributed to a weaker period effect in the working period of 
ICD 8 and ICD 9 (1969-1995). However, the cases excluded from ICD 8 and ICD 9 comprises juvenile and adult 
forms of muscular atrophies, which are not included in G12.2 in ICD 10.  Our selection of codes from the 
different ICDs is considered most consistent [3]. The El Escorial diagnostic criteria were revised in 1998 in 
Airlie House, including a probable form based on paraclinical data. The impact of these changes are considered 
small [27].  
As for all studies on incidence or mortality time trends, the issue of possible changes in case ascertainment 
applies for our study. General improvement of case ascertainment over time, especially amongst the oldest, is 
both possible and plausible. As the population older than 70 years in Norway has increased by 248% throughout 
the study period, improved case ascertainment among the elderly would have a great impact on our results. A 
great strengthening of neurological services has taken place during the study period. Thus, practicing 
neurologists or neurological departments were present in all counties from 1979. However, the increasing rates 
have continued also in the last two decades, when these factors are less likely to play a significant role. Moreover, 
there were no differences in mortality rates in the two largest cities (Oslo and Bergen) and in the rest of the 
country, arguing against a great impact of differences in case ascertainment between rural and urban areas.  This, 
and consistent findings from other countries [5,6,15-19], might substantiate that a real increase in ALS mortality 
has taken place.  
Systematic inaccuracies in recording number of deaths could also contribute to changes in rates. However, both 
in the current and earlier studies [28,13] ALS incidence data from hospital files match mortality data from 
NCoDR quite well. 
Age-period-cohort analyses have to be interpreted with caution. Because of the linear dependence of the 
regressor variables (age=period-cohort), it is not possible to attribute separate effects without further constraints 
[4]. Using different constraints can change not only the magnitude of the parameters, but also the direction of 
trend for each time factor, thus profoundly influencing the conclusion from an analysis.  
An additional model-related problem is that an age-period interaction could mimic a cohort effect. In our case, it 
is possible that case ascertainment has improved over time, and that this improvement has an age-gradient; more 
of the elderly being ascertained. This would result in an age-period interaction. The age-period-cohort model 
cannot separate between a cohort effect and an age-period interaction. The latter must therefore necessarily serve 
as an alternative explanation. However, restricting the age-period-cohort analysis to those below 70 years did not 
change the results. Additionally, the observed cohort effect between 1880 and 1934 is largely consistent with 
previous reports [5,6], altogether suggesting that this finding is valid. 
The earlier suggested spring [8]- or late autumn [12] birth effect could not be reproduced in our material. Recent 
critics stress the need for both birth period- and place adjustment when examining potential seasonal birth effects 
on adult disease [29,30]. We believe that our model more accurately took into account the confounding from 
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periodic variations in month of birth distribution. A larger material that allows adjusting for both time and place 
of birth is needed.  
In summary, we find increasing mortality from ALS throughout the whole study period. The effect of birth year 
on ALS mortality increased from 1860 to 1934, suggesting an effect of changing environmental exposures or life 
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